摘要
目的?观察黄芪辅佐治疗儿童变应性鼻炎的临床疗效及对血清 IL鄄4 的影响。方法: 例变应性鼻炎患儿随机分黄芪治疗组 3822 例和常规治疗对照组 16 例。两组均采用常规治疗,治疗组加用黄芪颗粒 1/2 包/次, 次/d,疗程 3 ￣ 6 月。观察患儿 1 周内症状缓 3解率、用药 3 个月内复发率及用药前和用药 3 个月后血清白介素 4( )水平的变化。结果:治疗组和对照组 1 周内症状缓解率无 IL鄄4显著差异(χ = 0.806, 2 P > 0.05), 个月内复发率治疗组显著低于对照组(χ = 4.674, < 0.05)。血清 IL鄄4 用药后治疗组下降显著 3 2 P高于对照组( q = 8.472, < 0.01),与正常组比较无显著差异( = 0.112, > 0.05),而对照组仍显著高于正常组( = 9.074, < P q P q P0.01)。结论:黄芪在佐治儿童变应性鼻炎中显著减少患儿的复发率及降低血清 IL鄄4 水平。
Objective: To study the supplementary therapy effect with astragalus on children with allergic rhinitis (AR) and the changes of serum interleukin-4 (IL-4) Methods: 38 children with AR were randomly divided into treatment group (22 cases) and control group (16 cases) with general treatment. The 7.5 g (1/2 bag) astragalus three times a day was added orally to treatment group for 3 to 6 months . The rates of remission within 1 week and relapse within 3 months were observed in both treatment group and control group. The levels of serum IL-4 were determined before astragalus being used and 3 months after the usage. And then the changes in serum IL-4 were observed in treatment group, control group and 25 cases as normal control group respectively. Results: The rate of remission within 1 week was not different in treatment and control group ( χ2 = 0.806, P > 0.05). The rate of relapse within 3 months was significantly lower in treatment group than those in control group ( χ2 = 4.674, P < 0.05). The level of serum IL-4 was significantly decreased more in treatment group than that in control group ( q= 8.472, P < 0.01) and not different in treatment group in comparison with normal control group ( q= 0.112, P > 0.05), but was significantly higher in control group than that in III group ( q= 9.074, P < 0.01) after astragalus therapy. Conclusion: Astragalus therapy can be helpful in diminishing relapse and the level of serum IL-4 of children with AR.
出处
《儿科药学杂志》
CAS
2004年第2期56-57,共2页
Journal of Pediatric Pharmacy
